Timpani Capital Management’s Supernus Pharmaceuticals SUPN Stock Holding History

Timpani Capital Management’s Portfolio SUPN Stock Details SUPN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q3	–	Sell	-71,529	Closed	-$4.28M	–	110
2018 Q2	$4.28M	Buy	71,529 +14,028	+24%	+$727K	1.26%	32
2018 Q1	$2.63M	Buy	57,501 +12,702	+28%	+$530K	0.92%	48
2017 Q4	$1.78M	Sell	44,799 -3,133	-7%	-$124K	0.64%	68
2017 Q3	$1.92M	Sell	47,932 -52,776	-52%	-$2.28M	0.7%	65
2017 Q2	$4.34M	Sell	100,708 -278	-0.3%	-$9.89K	1.61%	19
2017 Q1	$3.16M	Buy	100,986 +45,653	+83%	+$1.22M	1.27%	31
2016 Q4	$1.4M	Sell	55,333 -31,070	-36%	-$694K	0.58%	72
2016 Q3	$2.14M	Buy	+86,403	New	+$1.96M	0.85%	49
2014 Q4	–	Sell	-156,236	Closed	-$1.36M	–	98
2014 Q3	$1.36M	Buy	+156,236	New	+$1.41M	0.62%	61

Other funds holding SUPN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

CIP

Champlain Investment Partners Burlington, Vermont $7.88B AUM 6.82% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Glenmede Trust Philadelphia, Pennsylvania $20.4B AUM

Fiera Capital (Canada) Montreal, Quebec, Canada $29.2B AUM 20.16% 1-Year Est. Return

Timpani Capital Management's SUPN Position: Q3 2018 in Review

Timpani Capital Management sold out of Supernus Pharmaceuticals (SUPN) in Q3 2018, closing a stake of 71,529 shares — an estimated $4.28M sold.

Timpani Capital Management first reported a position in SUPN in Q3 2014 and held it in 9 quarters. The position peaked at $4.34M in Q2 2017. 288 funds tracked by Wall St. Rank hold SUPN as of Q3 2018.

Timpani Capital Management reported no remaining Supernus Pharmaceuticals position as of Q3 2018 after selling out during the quarter.
Timpani Capital Management sold 71,529 Supernus Pharmaceuticals shares in Q3 2018, an estimated $4.28M.
Timpani Capital Management first reported a position in Supernus Pharmaceuticals in Q3 2014 and held it in 9 quarters.
Timpani Capital Management's Supernus Pharmaceuticals position peaked at $4.34M in Q2 2017.
288 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q3 2018.

Based on Timpani Capital Management's 13F filing for Q3 2018, filed 13 Nov 2018.